Celularity announces fast track designation by the FDA for its natural killer cell therapy CYNK-001 in the treatment of recurrent glioblastoma multiforme

18 March 2021 - Celularity announced that the company has received fast track designation from the U.S. FDA for its non-genetically ...

Read more →

FDA permits marketing of first SARS-CoV-2 diagnostic test using traditional premarket review process

17 March 2021 - BioFire Respiratory Panel 2.1 is the first COVID-19 diagnostic test granted marketing authorisation using the de novo ...

Read more →

Sagimet Biosciences receives fast track designation from U.S. FDA for FASN inhibitor TVB-2640 in NASH

16 March 2021 - Sagimet Biosciences announced today that the U.S. FDA has granted fast track designation to TVB-2640 for ...

Read more →

U.S. plans to use real world and trial data to determine when vaccines need to be updated

17 March 2021 - U.S. officials plan to use data gathered from people who have already been vaccinated against COVID-19 as ...

Read more →

AbbVie announces extension of review for supplemental new drug application of upadacitinib for the treatment of adults with active psoriatic arthritis

17 March 2021 - AbbVie announced that the U.S. FDA has extended the review period for the supplemental new drug application ...

Read more →

Sparta Biomedical receives FDA breakthrough device designation for SBM-01 biomimetic implant

17 March 2021 - Sparta Biomedical today announced that its SBM-01 biomimetic implant has been granted a breakthrough device designation from ...

Read more →

Leveraging real world evidence in regulatory submissions of medical devices

16 March 2021 - Among the many ways that the U.S. FDA protects and promotes the public health is by ensuring ...

Read more →

Merck receives priority review from FDA for new drug application for HIF-2α inhibitor belzutifan (MK-6482)

16 March 2021 - Application based on objective response rate from Phase 2 trial evaluating belzutifan in patients with von Hippel-Lindau ...

Read more →

Confirmation of Technigas US FDA timetable

12 March 2021 - Cyclopharm has provided an update of the US FDA’s timetable in respect of approval of the Company’s ...

Read more →

Melinta Therapeutics announces FDA approval of Kimyrsa (ortivancin) for the treatment of adult patients with acute bacterial skin and skin structure infections

15 March 2021 - Single dose antibiotic with one hour infusion, additional compatibilities in normal saline and D5W, and lower infusion ...

Read more →

PharmaEssentia provides U.S. regulatory update on ropeginterferon alfa-2b-njft for the treatment of polycythemia vera

14 March 2021 - PharmaEssentia Corporation today announced that the U.S. FDA has issued a complete response letter for the ...

Read more →

BioXcel Therapeutics receives FDA breakthrough therapy designation for BXCL501 for the acute treatment of agitation associated with dementia

15 March 2021 - Designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options ...

Read more →

Calliditas announces submission of new drug application to U.S. FDA for Nefecon in patients with primary IgA nephropathy

15 March 2021 -  Calliditas Therapeutics today announced the submission of a new drug application to the U.S. FDA for ...

Read more →

Marius Pharmaceuticals receives PDUFA date for Kyzatrex NDA for treatment of hypogonadism

11 March 2021 - Marius Pharmaceuticals announced today that the U.S. FDA has assigned a Prescription Drug User Fee Act goal ...

Read more →

Revolutionary option for medical device sterilisation approved by FDA

11 March 2021 - The United States FDA newly approved chlorine dioxide gas for contract sterilisation of medical devices.  ...

Read more →